Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.
Fiche publication
Date publication
septembre 2022
Journal
Frontiers in cardiovascular medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Pr PIVOT Xavier, Dr CURTIT Elsa, Dr MANSI Laura, Dr VERNEREY Dewi, Dr MOUGIN-GUILLAUME Fabienne, Dr JACQUINOT Quentin
Tous les auteurs :
Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F
Lien Pubmed
Résumé
Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective supportive therapy in the management of side effects, but the cardioprotective effects of exercise are still unclear.
Mots clés
HER2 overexpression, breast cancer, cardiotoxicity, prevention, supervised exercise program, supportive care
Référence
Front Cardiovasc Med. 2022 09 23;9:1000846